Metastatic Synovial Sarcoma: Clinical Trials

5 trials for Metastatic Synovial Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 active not recruiting, 1 completed, 1 recruiting. 5 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 15Terminated 2, Active not recruiting 1, Completed 1, Recruiting 1
Phase 22Active not recruiting 1, Terminated 1

Follow Metastatic Synovial Sarcoma: new trials by email Literature Review of Metastatic Synovial Sarcoma trials Research Report on Metastatic Synovial Sarcoma

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
Phase 1RecruitingNational Cancer Institute (NCI)302024-02-062026-11-16
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma
Phase 1TerminatedFred Hutchinson Cancer Center272019-09-302024-05-08
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Phase 1 / Phase 2Active not recruitingRoswell Park Cancer Institute152017-07-142026-07-08
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma
Phase 1CompletedOHSU Knight Cancer Institute162017-03-102023-08-16
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)1512015-11-302022-08-23

Narrower conditions

Sarcoma, Synovial (5)  ·  Histiocytoma, Malignant Fibrous (4)  ·  Dermatofibrosarcoma (3)  ·  Leiomyosarcoma (3)  ·  Sarcoma (3)  ·  Liposarcoma (2)  ·  Neurofibrosarcoma (2)  ·  Chondrosarcoma (1)  ·  Disorders of Sex Development (1)  ·  Fallopian Tube Neoplasms (1)  ·  Fibrosarcoma (1)  ·  Hemangiosarcoma (1)  ·  Liposarcoma, Myxoid (1)  ·  Melanoma (1)  ·  Ovarian Neoplasms (1)

Broader conditions

Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms, Connective Tissue (5)  ·  Neoplasms, Connective and Soft Tissue (5)  ·  Histiocytoma (4)  ·  Neoplasms, Fibrous Tissue (4)  ·  Neoplasms, Adipose Tissue (3)  ·  Neoplasms, Muscle Tissue (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Endocrine System Diseases (2)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Fibrosarcoma (2)  ·  Gonadal Disorders (2)  ·  Nerve Sheath Neoplasms (2)

Interventions

Doxorubicin (2)  ·  Biopsy (1)  ·  Cyclophosphamide (1)  ·  Decitabine (1)  ·  INCB039110 (1)  ·  Injections (1)  ·  Leukapheresis (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  baricitinib (1)  ·  itacitinib (1)  ·  liposomal doxorubicin (1)  ·  pazopanib (1)  ·  peposertib (1)  ·  ribociclib (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Fred Hutchinson Cancer Center (1)  ·  OHSU Knight Cancer Institute (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (5)

Top investigators

Candace L Haddox (1)  ·  Lara E Davis (1)  ·  Lee Cranmer (1)  ·  Philip McCarthy, MD (1)  ·  William D Tap (1)

NIH funding

P30CA016056 (1), R01CA164333 (1), U10CA180821 (1), UM1CA186709 (1)